Skip to content
Homepage
Author:
Ascelia Pharma
Posted Date:
July 3, 2026
Ascelia Pharma Provides Update on the Orviglance NDA
Ascelia Pharma
July 3, 2026
Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing
Ascelia Pharma
June 30, 2026
Orviglance Data Presented Today at the Annual Radiology Congress ESGAR 2026
Ascelia Pharma
June 9, 2026
Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones
Ascelia Pharma
May 12, 2026
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026
Ascelia Pharma
May 4, 2026
Change in Number of Shares and Votes in Ascelia Pharma AB
Ascelia Pharma
April 30, 2026
Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026
Ascelia Pharma
April 9, 2026
Notice of Annual General Meeting in Ascelia Pharma AB
Ascelia Pharma
March 30, 2026
Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026
Ascelia Pharma
March 27, 2026
Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review
Ascelia Pharma
February 8, 2026
